MECHANISM OF ACTION

Mechanism of Action Tenofoviralafenamide is a phosphonamidateprodrug of tenofovir (2’-deoxyadenosine monophosphate analog). Tenofoviralafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofoviralafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes.

Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovirdiphosphate. Tenofovirdiphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination. Tenofovirdiphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.

CORPORATE ADDRESS

Beacon Pharmaceuticals Limited
9/A,Toyenbee Circular Road,
Motijheel,Dhaka-1208, Bangladesh.
Phone: +880-2-57165371-79
Fax: +880 2-57165380
Web: beaconpharma.com.bd

ALTERNATIVE CONTACT 1

Skype ID: shahariar_tamal
WhatsApp: +8801922121404
WeChat: +8801922121404
IMO: +8801922121404
Viber: +8801922121404
Email: tamal-tsd@beaconpharma.com.bd
beaconbdd@gmail.com

ALTERNATIVE CONTACT 2

Skype ID: masfikur.rahman
WhatsApp: +8801730026182
IMO: +8801730026182
Viber: +8801730026182
Email: masfik@beaconpharma.com.bd